Astellas Pharma Gmbh

Yamanouchi Pharmaceutical Company Ltd.

Helix Research Institute

Jun Takasaki

Masazumi Kamohara

Mitsuyuki Matsumoto

Tetsu Saito

Hiroyuki Moritomo

Fukushi Hirayama

Yuji Koga

Takao Okuda

Susumu Watanuki

Masato Kobayashi

Toru Sugimoto

Takashi Kamikubo

Takao Isogai

Tetsuo Nishikawa

Toshio Ota

Issei Tsukamoto

Takatoshi Soga

Daisuke Kaga

Jiro Fujiyasu

Hirotsugu Tanaka

Atsuo Yonezawa

Takahide Ohishi

Yuri Kawai

Eiji Yoshimi

Michihito Kageyama

Tohru Sugimoto

Yukari Koya

Toshio Uemura

Yumiko Moritani

Satoshi Takeuchi

Koji Aoyama

Shinji Soga

Masahito Sato

Jotarou Suzuki

Chie Okuyama

The present application provides a bispecific antibody for preventing or treating an immune inflammatory disease by acting on both human TLR2 and human TLR4 to inhibit human TLR2- and human TLR4-mediated immune inflammatory effects. More specifically, the provided bispecific antibody is a bispecific antibody for human TLR2 and human TLR4, including a heavy chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 4; a light chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 113 of SEQ ID NO: 6; a heavy chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 491 to 609 of SEQ ID NO: 4; and a light chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 625 to 732 of SEQ ID NO: 4.

Bispecific antibody binding to human TLR2 and human TLR4

Anti-human NGF antibodies are useful for treating pain.

Method of treating pain with anti-human NGF antibody

[Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab' fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.

Anti-human NGF antibody

Disclosed are quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; &#x2014;N(R)C(O)-lower alkylene-COR, lower alkylene-COR, lower alkenylene-COR, &#x2014;O-lower alkylene-COR, &#x2014;O-(lower alkylene which may be substituted with &#x2014;COR)-aryl or &#x2014;O-lower alkenylene-COR(wherein Ris H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof, has excellent P2Y12 inhibitory activity. The quinolone derivatives have excellent platelet aggregation inhibitory activity. A method of using the compounds is also disclosed.

Quinolone derivative or pharmaceutically acceptable salt thereof

Provided are quinolone derivatives having a lower alkyl or cycloalkyl at the 1-position; &#x2014;N(R)C(O)-lower alkylene-COR, lower alkylene-COR, lower alkenylene-COR, &#x2014;O-lower alkylene-COR, &#x2014;O-(lower alkylene which may be substituted with &#x2014;COR)-aryl or &#x2014;O-lower alkenylene-COR(wherein Ris H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof. Pharmaceutical composition containing the quinolone derivatives and methods of using the compositions are provided.

A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.

Quinolone derivative or salt thereof

The invention relates to a convenient screening tool for identifying an agent for treating diabetes. The screening tool is a G protein-coupled receptor, a variant of the G protein-coupled receptor, or a homolog of the G protein-coupled receptor, which promotes insulin secretion under a high glucose concentration by activation. The invention also relates to cells transformed with an expression vector comprising a polynucleotide encoding and expressing the screening tool. The invention provides a convenient screening method for identifying an agent for treating diabetes, pharmaceutical compositions comprising the agent, and a process for manufacturing the pharmaceutical composition.

Method for screening agents for the treatment of diabetes

A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2Tprotein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2Tligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.

Method of screening antiplatelet agents

This invention belongs to the genetic engineering field, and provides novel G protein-coupled receptor family proteins SREB1, SREB2 and SREB3 expressed in the central nervous system, genes coding for these proteins, screening methods using these proteins and so on. As one of the methods for obtaining the G protein-coupled receptor proteins of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.

Polynucleotides encoding SREB1 receptor

A cDNA encoding a novel LTCreceptor has been isolated. Provision of the novel protein, an LTCreceptor, enabled binding experiments using the LTC. By screening for compounds that modulate LTCreceptor activity based on these binding experiments, development of drugs targeting the LTCreceptor becomes possible.

Peptide leukotriene receptor

Polynucleotides encoding SREB3 receptor

This invention belongs to the genetic engineering field, and provides the novel G protein-coupled receptor family protein SREB2 expressed in the central nervous system, genes coding for the protein, screening methods using the protein and so on. As one of the methods for obtaining the G protein-coupled receptor protein of the present invention, RT-PCR is carried out using mRNA extracted from human or rat brain tissue or brain-derived cells as the template and using two primers interposing the entire portion or a part of the G protein-coupled receptor protein translation region, thereby obtaining cDNA corresponding to the G protein-coupled receptor protein or a part thereof, and the cDNA is integrated into an appropriate expression vector and expressed in a host cell.

Polynucleotides encoding SRE B2 receptor

Growing community of inventors

Tokyo, Japan

Jun Takasaki